Since 1998, Mr. Pfanzelter has been on the board of directors of Doctor’s Associates, the parent company of Subway Restaurants, the nation’s largest restaurant chain. In February 2012, Dave joined Wrigley Foods Advisory Board of Directors. He also served on the Board of the International Food Service Manufacturer’s Association as chairman and member of its executive committee.Dr. Theno is currently the chief executive officer of Gray Dog Partners, Inc., a technical consulting firm specializing in food safety and manufacturing, restaurant operations, supply chain management, strategic planning and facility design. Gray Dog Partners also provides consultation to federal, state and local regulatory bodies, including the U.S. Department of Agriculture (USDA), the U.S. Food and Drug Administration, the USDA’s Agricultural Marketing Service, and state and local health departments. Dr. Theno is widely respected in the food industry and is a frequent senior contributing editor for several trade journals as well as a keynote speaker for numerous national associations in the food industry. From 1993 to 2009, Dr. Theno served Jack in the Box Inc. as the corporate vice president – technical services, followed by his appointment as senior vice president and chief food safety officer. Prior to that, he spent six years as managing director and chief executive officer of Theno & Associates, a private contracting firm that supplied complete technical service resources to multiple facets of the food industry. Dr. Theno’s professional experience also includes executive positions in technical services and quality control at Foster Farms, Kellogg Company and Armour Food Company. Dr. Theno and Mr. Pfanzelter join food microbiology expert, Robert Deibel, Ph.D., on PURE’s Advisory Panel. Dr. Deibel joined the Advisory Panel in May 2011. About PURE Bioscience, Inc. PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, the Company’s failure to implement or otherwise achieve the benefits of its strategic initiatives, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.